- $37.77bn
- $45.25bn
- $32.72bn
CRH expects U.S. profit boost but says Europe remains challenging
Brief: CRH sees H1 sales, EBITDA up year-on-year after strong U.S. start
Trading Update – April 2023
Holding(s) in Company
CRH publishes restated segment information
EU permits to boost profitability in cement though volumes fall - GS
CRH to quit Dublin exchange - Irish Times
Director/PDMR Shareholding
UK's OKYO Pharma plans to delist from London in May (updated)
Brief: CRH Completes Latest Phase Of Co's Share Buyback Programme
Director Declaration
AGM Notice and Form of Proxy
CRH Announces Non-Executive Board Appointment
Annual Financial Report
Director/PDMR Shareholding
Transatlantic valuation gap is mostly illusory
Director/PDMR Shareholding
SoftBank snub shows London risks losing its listings lustre
SoftBank snub shows London risks losing its listings lustre